As we observed that inhibition of AR activity with AT-001 alleviates diastolic dysfunction and adverse cardiac remodeling in type 2 diabetes, AR inhibitors may represent an exciting approach to extinguish type 2 diabetes-related cardiovascular disease that is characterized by diastolic dysfunction. Here, AR is linked to cardiovascular disorder.